drugset / Trial / NCT04556266
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The purposed of this study is to determine whether an infusion with specialized 'modified T cells' (or CD19 chimeric antigen T cells, also called CD19 CAR T cells) that target the B cell marker will reduce the risk of relapse after transplant.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2022-03-01
- Completion
- 2022-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T cells | Cell therapy | 10000 cells/kg | — |
| Subject | CD19 CAR-T cells | Cell therapy | 100000 cells/kg | — |
| Subject | CD19 CAR-T cells | Cell therapy | 200000 cells/kg | — |
| Subject | CD19 CAR-T cells | Cell therapy | 400000 cells/kg | — |